Stockwatch: Amphastar’s Turn Away From Generics
Specialty Pharma Treads A Precarious Path Between Pharma And Generics
Amphastar’s 2020 financial results included its best ever quarter and a different revenue pattern from most pharma and generic companies. Its evolving product mix and marketing campaigns were two reasons for its performance.
You may also be interested in...
If demand-side pressures on the life science sector were not enough, generic price erosion, debt repayment and extended restructurings are worsening the generic pharmaceutical investment proposition.
Amphastar has secured the first US approval for a generic version of Eli Lilly’s glucagon emergency kit.
The FDA’s rejection of Acadia’s label expansion into a broader patient population for its only approved drug resulted in an aggrieved reaction. Better disclosure from both sides would have helped.